Organon & Co
Open
SectorHealthcare
13.53 0.07
Overview
Share price change
24h
Min
13.52
Max
13.53
Income | 351M 146M |
|---|---|
Sales | -47M 1.5B |
P/E Sector Avg | 14.505 62.58 |
EPS | 0.71 |
Dividend yield | 0.59 |
Profit margin | 10 |
Employees | 10,000 |
EBITDA | 344M 409M |
Dividend yield Sector Avg | 0.59% 2.19% |
|---|---|
Next Earnings | 4 Aug 2026 |
Next Dividend date | 10 Sept 2026 |
Next Ex Dividend date | 14 Aug 2026 |
Market Cap | 87M 3.5B |
|---|---|
Previous open | 13.46 |
Previous close | 13.53 |
News Sentiment
By Acuity
54%
46%
272 / 340 Healthcare
Organon & Co Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Organon & Co Forecast
Sentiment
By Acuity
272 / 340 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Organon & Co
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
